Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement stock options to 11 new employees. The awards, issued under the Company's 2023 Inducement Plan, allow for the purchase of up to 167,400 shares of common stock.
The stock options feature a four-year vesting schedule, with 25% of shares vesting after one year and the remaining vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale specializzata in terapie oncologiche, ha concesso opzioni azionarie di incentivo a 11 nuovi dipendenti. Gli incentivi, emessi ai sensi del Piano di Incentivazione 2023 della Societ脿, consentono l'acquisto di fino a 167.400 azioni ordinarie.
Le opzioni prevedono un piano di maturazione quadriennale: il 25% delle azioni matura dopo un anno e il restante viene maturato mensilmente al ritmo di 1/48 nei successivi 36 mesi, subordinatamente alla permanenza in servizio.
Syndax Pharmaceuticals (NASDAQ: SNDX), una compa帽铆a biofarmac茅utica en etapa comercial centrada en terapias contra el c谩ncer, ha concedido opciones sobre acciones de incentivo a 11 nuevos empleados. Las adjudicaciones, emitidas bajo el Plan de Incentivos 2023 de la Compa帽铆a, permiten la compra de hasta 167.400 acciones ordinarias.
Las opciones tienen un calendario de adquisici贸n de derechos de cuatro a帽os: el 25% de las acciones se adjudica despu茅s de un a帽o y el resto se adquiere mensualmente a raz贸n de 1/48 durante los siguientes 36 meses, condicionado a la continuidad en el empleo.
Syndax Pharmaceuticals (NASDAQ: SNDX), 鞎� 旃橂鞝滌棎 欤茧牓頃橂姅 靸侅梾 雼硠鞚� 氚旍澊鞓れ牅鞎巾殞靷靹� 11氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞛ル牑 靹标博鞚� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐枅鞀惦媹雼�. 鞚� 靾橃棳電� 須岇偓鞚� 2023雲� 鞙犾澑 瓿勴殟(Inducement Plan)鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 氤错喌欤� 斓滊寑 167,400欤�毳� 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ毳� 韽暔頃╇媹雼�.
鞓奠厴鞚� 4雲� 氩犾姢韺�(甓岆Μ頇曥爼) 鞚检爼鞙茧 甑劚霅橂┌, 25%電� 1雲� 頉勳棎 甓岆Μ臧� 頇曥爼霅橁碃 雮橂ǜ歆� 欤检嫕鞚� 鞚错泟 36臧滌洈 霃欖晥 毵れ洈 1/48 牍勳湪搿� 頇曥爼霅╇媹雼�. 雼�, 歆�靻嶌爜鞚� 瓿犾毄鞚� 鞝勳牅 臁瓣贝鞛呺媹雼�.
Syndax Pharmaceuticals (NASDAQ: SNDX), une soci茅t茅 biopharmaceutique en phase commerciale sp茅cialis茅e dans les th茅rapies contre le cancer, a attribu茅 des options d'achat d'actions incitatives 脿 11 nouveaux employ茅s. Les attributions, 茅mises dans le cadre du Plan d'Incitation 2023 de la soci茅t茅, permettent l'achat de jusqu'脿 167 400 actions ordinaires.
Les options suivent un calendrier d'acquisition de droits sur quatre ans : 25% des actions sont acquises apr猫s un an et le reste est acquis mensuellement 脿 raison de 1/48 sur les 36 mois suivants, sous r茅serve de la continuit茅 de l'emploi.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein im kommerziellen Stadium befindliches Bio颅pharma颅unternehmen mit Fokus auf Krebstherapien, hat Anreiz鈥慉ktienoptionen an 11 neue Mitarbeiter gew盲hrt. Die Zuwendungen, ausgegeben im Rahmen des Inducement Plans 2023 der Gesellschaft, erm枚glichen den Erwerb von bis zu 167.400 Stammaktien.
Die Optionen sehen einen vierj盲hrigen Vesting鈥慞lan vor: 25% der Aktien werden nach einem Jahr f盲llig, der Rest vestet monatlich mit einer Rate von 1/48 眉ber die folgenden 36 Monate, vorausgesetzt, die Besch盲ftigung besteht fort.
- None.
- None.
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq:聽), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025聽the Company granted inducement awards to purchase up to 167,400 shares of common stock to 11 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj庐聽(revumenib), an FDA-approved menin inhibitor, and Niktimvo鈩� (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit聽聽or follow the Company on聽 补苍诲听.
Syndax Contact
Sharon Klahre聽
Syndax Pharmaceuticals, Inc.聽
Tel 781.684.9827
FAQ
What type of stock options did Syndax Pharmaceuticals (SNDX) grant in September 2025?
How do the vesting terms work for Syndax's September 2025 inducement grants?
How many new employees received Syndax stock options in September 2025?
What is the purpose of Syndax's inducement grants under NASDAQ Rule 5635(c)(4)?
